Given that sustained inflammation is a hallmark of SLE, the novel C-reactive protein (CRP)–triglyceride–glucose (TyG) index (CTI), which comprehensively reflects insulin resistance and inflammation, has emerged as a valuable biomarker. This evidence concerns the gene CRP and systemic lupus erythematosus.